Soo-Yong Tan
Overview
Explore the profile of Soo-Yong Tan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malinowski D, Callaghan R, Whitehead C, Nelson R, Allen L, Purnell D, et al.
Am J Clin Pathol
. 2024 Jun;
PMID: 38913880
Objectives: The benefits of liquid-based cytology (LBC) in routine cervical cancer screening are often associated with the availability of instrumented platforms and economic considerations. A low-cost alternative to LBC in...
2.
Hoppe M, Jaynes P, Shuangyi F, Peng Y, Sridhar S, Hoang P, et al.
Cancer Discov
. 2023 Apr;
13(5):1144-1163.
PMID: 37071673
Significance: Using single-cell-resolved multiplexed imaging, we show that selected subpopulations of cells expressing specific combinations of oncogenes influence clinical outcomes in lymphoma. We describe a probabilistic metric for the estimation...
3.
Ran X, Ding L, Sun Q, Yang H, Said J, Zhentang L, et al.
Cancer Res
. 2023 Jan;
83(6):922-938.
PMID: 36638333
Significance: Targeting XRN1 activates an intracellular innate immune response mediated by RNA-sensing signaling and potentiates cancer immunotherapy efficacy, suggesting inhibition of RNA decay machinery as a novel strategy for cancer...
4.
Ting C, Tan S, Gan G, Zain S, Pung Y, Ong D, et al.
Int J Lab Hematol
. 2022 Jul;
44(5):907-917.
PMID: 35830966
Introduction: Routine categorization of DLBCL patients into GCB and non-GCB groups by Hans' criteria could not accurately predict chemotherapy resistance and disease progression in patients treated with standard R-CHOP therapy....
5.
Hue S, Ng S, Wang S, Tan S
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626087
The intestinal immune system, which must ensure appropriate immune responses to both pathogens and commensal microflora, comprises innate lymphoid cells and various T-cell subsets, including intra-epithelial lymphocytes (IELs). An example...
6.
Wai C, Chen S, Phyu T, Fan S, Leong S, Zheng W, et al.
Haematologica
. 2022 Jan;
107(8):1864-1879.
PMID: 35021606
Primary Epstein-Barr virus (EBV)-positive nodal T/NK-cell lymphoma (PTCL-EBV) is a poorly understood disease which shows features resembling extranodal NK/T-cell lymphoma (ENKTL) and is currently not recognized as a distinct entity...
7.
Lee W, Ye Z, Cheung A, Goh Y, Oh H, Rajarethinam R, et al.
Mol Cancer Ther
. 2021 Jun;
20(9):1702-1712.
PMID: 34158344
Acute myeloid leukemia (AML) is an aggressive disease with poor outcomes, overwhelmingly due to relapse. Minimal residual disease (MRD), defined as the persistence of leukemic cells after chemotherapy treatment, is...
8.
Susan S, Ng S, Wang S, Tan S
Semin Diagn Pathol
. 2021 May;
38(4):21-30.
PMID: 34016481
Most gastrointestinal NK and T cell lymphomas are aggressive in behavior, although in recent years a subset of indolent lymphoproliferative disorders have been described, which must be distinguished from their...
9.
Oon M, Lim J, Lee B, Leong S, Soon G, Wong Z, et al.
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33477749
T-cell lymphomas arise from a single neoplastic clone and exhibit identical patterns of deletions in T-cell receptor (TCR) genes. Whole genome sequencing (WGS) data represent a treasure trove of information...
10.
Ting C, Gan G, Ong D, Tan S, Bee P
Int J Clin Pract
. 2020 Jun;
74(10):e13594.
PMID: 32583545
Background: About 20%-30% of diffuse large B-cell lymphoma (DLBCL) patients experience early disease progression despite R-CHOP chemotherapy treatment. Revised international prognostic index (R-IPI) score could risk stratify DLBCL patients but...